New high-cost HIV prevention drug: 'Better' isn't worth it

https://www.eurekalert.org/pub_releases/2020-03/ysop-nhh030420.php

News Release 9-Mar-2020
Yale School of Public Health

A newly approved drug for HIV pre-exposure prophylaxis (PrEP) is unlikely to confer any discernible health benefit over generic alternatives and may undermine efforts to expand access to HIV prevention for the nation's most vulnerable populations, according to a new study appearing today (March 9) in the Annals of Internal Medicine.

•••••